If a potential corporate deal have been discounted, I think that would be a mistake. Large cap healthcare valuations has held up very well during this crisis and with the AUD weakness it is a conducive to deal making with small cap Aussie biotechs. Maybe with some of the economic uncertainty around, OPT management might be even more inclined to be doing deals or even open to a TO. My impression prior to COVID-19 was they wanted to go it alone for as long as they could afford, but that may have changed now.
Industry Mag, page-25
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.8¢ |
Change
-0.018(3.10%) |
Mkt cap ! $674.0M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.0¢ | 53.0¢ | $363.1K | 667.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 19116 | 54.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 42794 | 9 |
View Market Depth
| Last trade - 14.02pm 04/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |